Systemic sclerosis & Raynaud's
Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort
Authors' conclusion
JAKi showed similar effectiveness compared to standard-of-care immunosuppressants.
Study context
- Population
- Patients with SSc in the EUSTAR cohort36 JAK inhibitors (JAKi)-treated of 19,601
- Exposure
- JAKi vs conventional immunosuppressants
- JAKin = 36
- Outcome
- Safety and drug survival
Methodological detailslongitudinal, nearest-neighbor propensity score matching, EUSTAR cohort
- Longitudinal
- Nearest-neighbor propensity score matching
- EUSTAR cohort
Main finding
As reported in the abstract
Adverse events over 98.7 patient-years
23
Permanent treatment discontinuation
39%
Transient treatment discontinuation
19%
Observational data: associations, not effects.
Secondary outcomes
Change in forced vital capacity (FVC)% (lung function), stable · 12 months
- Mean FVC% change with JAKi; P = 0.530
- +1.7%
- Comparable to mycophenolate mofetil (MMF), rituximab (RTX) and methotrexate (MTX)
Change in modified Rodnan skin scores (mRSS) (skin fibrosis) in diffuse cutaneous SSc (dcSSc), numerical improvement · 12 months
- Mean mRSS change with JAKi
- −1.8
- Comparable to MMF, RTX and MTX
Swollen joint count change in baseline synovitis
- Median change with JAKi; P = 0.052
- −1
Digital ulcer (DU) recurrence and disease progression events
- Comparable to matched immunosuppressive groups
Calcinosis
- No new calcinotic burden observed
Safety
Adverse events with JAKi over 98.7 patient-years
- Adverse events
- 23
- Infections
- 12
- Laboratory abnormalities
- 7
- Malignancies
- 3
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →